Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENTIS BIOMATERIALS LTD.RGNT · Entity 7824 | Director | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENTIS BIOMATERIALS LTD.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 · Expires 2036-06-04 | Direct | 24,826 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 24,826 · Balance 24,826 F1: This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026. F2: This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
F2: This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 13, 2026 21:07 UTC | REGENTIS BIOMATERIALS LTD. RGNT · Entity 7824 | GrantEmployee Stock Option (Right to Buy) · Derivative | 24,826 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001213900-26-077638 · ownership.xml · derivative · entry 1 Alpert Susan PHD MD · CIK 0001204668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,826 Underlying: Ordinary Shares · 24,826 shares Expires 2036-06-04 F1 · security: This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026. F2 · security: This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.